American Association for Cancer Research

Program

Frontiers in Cancer Prevention Research 2012

* - short talk from proffered paper

TUESDAY, OCTOBER 16

PROFESSIONAL ADVANCEMENT SESSION

Session Chairperson: Steven M. Dubinett, David Geffen School of Medicine at UCLA, Los Angeles, CA
12:00 p.m.-1:30 p.m.

C3=Success
Ernest T. Hawk, University of Texas MD Anderson Cancer Center, Houston, TX

Finessing the review process: Success in getting published
Scott M. Lippman, Moores Cancer Center, University of California, La Jolla, CA

    Roundtable Mentors:
  • Jonathan Braun, UCLA Medical Center, Los Angeles, CA
  • Nancy H. Colburn, National Cancer Institute, Frederick, MD
  • Andrew J. Dannenberg, Weill Medical College of Cornell University, New York, NY
  • Phillip A. Dennis, Johns Hopkins University, Baltimore, MD
  • Steven M. Dubinett, David Geffen School of Medicine at UCLA, Los Angeles, CA
  • Ernest T. Hawk, University of Texas MD Anderson Cancer Center, Houston, TX
  • Dimitrios Iliopoulos, David Geffen School of Medicine at UCLA, Los Angeles, CA
  • Scott M. Lippman, Moores Cancer Center, University of California, La Jolla, CA

EDUCATIONAL SESSIONS 1-2

1:30 p.m.-3:00 p.m.

  • EDUCATIONAL SESSION 1: DESIGN AND EXECUTION OF CANCER PREVENTION STUDIES

    Session Chairperson: J. Jack Lee, The University of Texas MD Anderson Cancer Center, Houston, TX

    Report card for chemoprevention trials: The good, the bad and the ugly – How can we do better?
    J. Jack Lee

    Methodologic considerations for large-scale prevention trials: Lessons from the Women's Health Initiative
    Garnet L. Anderson, Fred Hutchinson Cancer Research Center, Seattle, WA

    Planning, design, and execution of cancer screening and early detection trials: Application to the National Lung Screening Trial (NLST)
    Ping Hu, National Cancer Institute, Bethesda, MD

  • EDUCATIONAL SESSION 2: HOW CAN WE USE MOUSE MODELS FOR PREVENTION RESEARCH?

    Session Chairperson: Leisa Johnson, Genentech, Inc., South San Francisco, CA

    Introduction
    Leisa Johnson

    Defining the site of origin and precursor lesions for high-grade serous ovarian cancer
    Daniela M. Dinulescu, Harvard Medical School, Boston, MA

    Targeting tumor-initiating cells in genetically engineered mouse models of non-small cell lung cancer
    Erica L. Jackson, Genentech, Inc., South San Francisco, CA

    Animal models for human pancreatic cancer prevention
    Chinthalapally V. Rao, University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Using mouse models to develop new drugs and strategies for prevention
    Karen T. Liby, Geisel School of Medicine at Dartmouth, Hanover, NH

EDUCATIONAL SESSIONS 3-4

3:10 p.m.-4:40 p.m.

  • EDUCATIONAL SESSION 3: NEW APPROACHES FOR BIOMARKER DISCOVERY

    Session Chairperson: Nancy H. Colburn, National Cancer Institute, Frederick, MD

    Introduction: How to identify biomarkers that predict compliance and efficacy
    Nancy H. Colburn

    Biomarker statistical designs
    Ziding Feng, Fred Hutchinson Cancer Research Center, Seattle, WA

    Dietary interventions to prevent colon cancer and discover biomarkers in mice and humans
    Nancy H. Colburn

  • EDUCATIONAL SESSION 4: CHARACTERIZING AND MONITORING THE MICROBIOME AS A MODIFIABLE DISEASE FACTOR

    Session Chairperson: Jonathan Braun, UCLA Medical Center, Los Angeles, CA

    Defining and monitoring microbial networks
    Jonathan Braun

    Diet and the gut microbiome: Who's feeding who?
    Johanna W. Lampe, Fred Hutchinson Cancer Research Center, Seattle, WA

    Genomic profiles of infection-related cancers in Asia
    Patrick Tan, Duke-NUS Graduate Medical School, Cancer Science Institute of Singapore, Genome Institute of Singapore, Singapore

EDUCATIONAL SESSIONS 5-6

4:50 p.m.-6:20 p.m.

  • EDUCATIONAL SESSION 5: HOW TO ESTABLISH TRANSDISCIPLINARY RESEARCH TEAMS

    Session Chairperson: Stephen D. Hursting, University of Texas, Austin, TX

    Diet, physical activity and the prevention of obesity-related breast cancer: Lessons learned from transdisciplinary research
    Stephen D. Hursting

    The Clinical and Translational Science Award Program: Transdisciplinary teams in cancer prevention research
    Steven M. Dubinett, David Geffen School of Medicine at UCLA, Los Angeles, CA

    Building transdisciplinary teams to address cancer health disparities: The Centers for Population Health and Health Disparities experience
    Electra D. Paskett, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • EDUCATIONAL SESSION 6: NONCODING RNAS: NEW PLAYERS IN THE CANCER PREVENTION FIELD

    Session Chairperson: Dimitrios Iliopoulos, David Geffen School of Medicine at UCLA, Los Angeles, CA

    Noncoding RNA feedback loop circuits in oncogenesis
    Dimitrios Iliopoulos

    microRNAs and cancer progression
    Carlo M. Croce, The Ohio State University Comprehensive Cancer Center, Columbus, OH

    Circulating microRNAs as cancer biomarkers
    Muneesh Tewari, Fred Hutchinson Cancer Research Center, Seattle, WA

OPENING PLENARY SESSION

6:30 p.m.-8:30 p.m.

Welcome and Opening Remarks
Raymond N. DuBois, The University of Texas MD Anderson Cancer Center, Houston, TX
Cory Abate-Shen, Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY

Keynote Lecture: Global Initiatives in Prevention Research
William G. Nelson, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Keynote Lecture: Accelerating Cancer Prevention Through Individual Behavior and Public Health Approaches
Graham A. Colditz, Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO

Distinguished Lecture on Targets for Cancer Prevention
Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA

OPENING RECEPTION

8:30 p.m.-10:30 p.m.

 

WEDNESDAY, OCTOBER 17

FORUM 1: OVERSCREENING, OVERDIAGNOSIS, AND OVERTREATMENT IN CANCER: THE PROSTATE EXAMPLE

Session Chairperson: Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, TX
7:00 a.m.-8:00 a.m.

Estimating how many prostate cancers are overdiagnosed: Overcoming challenges and avoiding mistakes
Ruth B. Etzioni, Fred Hutchinson Cancer Research Center, Seattle, WA

Finding common ground on the prostate cancer screening controversy
E. David Crawford, University of Colorado Cancer Center, Aurora, CO

Discussion / Q&A

PLENARY SESSION 1: PREVENTION ACROSS THE LIFECOURSE

Session Chairperson: Cheryl Lyn Walker, Texas A&M University Health Science Center, Houston, TX
8:00 a.m.-10:00 a.m.

The role of telomeres and telomerase in aging and cancer
Jerry W. Shay, UT Southwestern Medical Center, Dallas, TX

Early life environmental exposures, sentinel reproductive events, and cancer risk in women
Michele R. Forman, University of Texas, Austin, TX

Developmental reprogramming of cancer susceptibility
Cheryl Lyn Walker

Stress and the social environment: Impact on cancer risk
Suzanne D. Conzen, University of Chicago, Chicago, IL

CONCURRENT SESSIONS 1-2

10:15 a.m.-12:00 p.m.

  • CONCURRENT SESSION 1: INTERSECTION BETWEEN CANCER AND OTHER DISEASES: COPD, HIV, AND AUTOIMMUNE DISEASE

    Session Chairperson: Phillip A. Dennis, Johns Hopkins University, Baltimore, MD

    Inflammation links COPD/emphysema and lung cancer
    A. McGarry Houghton, Fred Hutchinson Cancer Research Center, Seattle, WA

    Epidemiology and pathogenesis of cancer in the setting of HIV infection
    Corey Casper, Fred Hutchinson Cancer Research Center, Seattle, WA

    Autoimmune rheumatic diseases and cancer: Not just chance?
    Antony Rosen, Johns Hopkins University, Baltimore, MD

    Systemic inhibition of receptor tyrosine kinase signaling by metformin *
    Brendan Quinn, Johns Hopkins University, Baltimore, MD

  • CONCURRENT SESSION 2: RISK ASSESSMENT

    Session Chairperson: Xifeng Wu, The University of Texas MD Anderson Cancer Center, Houston, TX

    Health screening cohort: A new avenue for risk prediction, prevention, and early detection research
    Xifeng Wu

    Malignant risk prediction for patients with oral premalignant lesions
    Miriam P. Rosin, BC Cancer Agency, Vancouver, BC, Canada

    Genomic-targeted approach to PSA screening and chemoprevention of prostate cancer
    Jianfeng Xu, Wake Forest University School of Medicine, Winston-Salem, NC

    Breast cancer risk assessment: Genetic and non-genetic risk factors contributing to differential model performance*
    Mary Beth Terry, Columbia University, New York, NY

POSTER SESSION A / LUNCH

12:00 p.m.-2:30 p.m.

  • Behavioral and Social Science
  • Biomarkers and Early Detection Research
  • Carcinogenesis
  • Cell, Molecular, and Tumor Biology
  • Chemoprevention and Biological Therapies
  • Epidemiology / Lifestyle Factors

SPECIAL SESSION: CANCER PREVENTION CLINICAL TRIALS

Session Chairperson: Eva Szabo, National Cancer Institute, Bethesda, MD
2:30 p.m.-3:30 p.m.

Metformin effects on breast preneoplasia
Andrea Decensi, E.O. Ospedali Galliera, Genova, Italy

The Costa Rica HPV Vaccine Trial: Vaccine efficacy against oral HPV infection and other novel findings
Aimée R. Kreimer, National Cancer Institute, Bethesda, MD

A randomized trial of a multivitamin in the prevention of cancer in men: The Physicians’ Health Study II
J. Michael Gaziano, Brigham and Women's Hospital, Boston, MA

PLENARY SESSION 2: INFLAMMATION AND CANCER

Session Chairperson: Andrew J. Dannenberg, Weill Medical College of Cornell University, New York, NY
3:30 p.m.-5:30 p.m.

Inflammation, stem cells, and cancer
Timothy C. Wang, Columbia University Medical Center, New York, NY

Helicobacter gastritis, metaplasia, and gastric cancer
Juanita L. Merchant, University of Michigan, Ann Arbor, MI

Inflammatory mediators, NSAIDs, and colorectal cancer
Raymond N. DuBois, The University of Texas MD Anderson Cancer Center, Houston, TX

The obesity-inflammation connection: Implications for breast carcinogenesis
Andrew J. Dannenberg

THE ELEVENTH ANNUAL AACR-PREVENT CANCER FOUNDATION AWARD LECTURE FOR EXCELLENCE IN CANCER PREVENTION RESEARCH

5:30 p.m.-6:30 p.m.

Progress in the prevention of hormonally regulated cancers
Jack Cuzick, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom

 

THURSDAY, OCTOBER 18

FORUM 2: CANCER PREVENTION: LESSONS LEARNED AND PROSPECTS FOR FUTURE DRUG DEVELOPMENT

Session Co-Chairpersons: Victoria M. Richon, Epizyme, Inc,. Cambridge, MA, and Jaye L. Viner, Millennium Pharmaceuticals, Cambridge, MA
7:00 a.m.-8:00 a.m.

Lessons learned from 20 years of chemoprevention research
Victor G. Vogel, Geisinger Health Systems, Danville, PA

What are the hurdles for moving approved drugs into the prevention setting?
Pamela M. Munster, University of California, San Francisco, CA

Discussion / Q&A

PLENARY SESSION 3: OBESITY, DIABETES, AND METABOLIC SYNDROME

Session Chairperson: Reuben J. Shaw, Salk Institute for Biomedical Studies, La Jolla, CA
8:00 a.m.-10:00 a.m.

The nutrient-sensing mTOR pathway in cancer initiation and progression
Brendan Manning, Harvard School of Public Health, Boston, MA

Regulation of tumor metabolism by sirtuins
Marcia C. Haigis, Harvard Medical School, Boston, MA

The LKB1-AMPK pathway coordinates metabolic reprogramming with growth control
Reuben J. Shaw

Role of autophagy in cancer
Eileen P. White, UMDNJ-The Cancer Institute of New Jersey, New Brunswick, NJ

CONCURRENT SESSIONS 3-4

10:15 a.m.-12:00 p.m.

  • CONCURRENT SESSION 3: CURRENT CONTROVERSIES IN CANCER SCREENING

    Session Chairperson: Electra D. Paskett, The Ohio State University Comprehensive Cancer Center, Columbus, OH

    Introduction
    Electra D. Paskett

    Predictors of change in colorectal cancer screening decision stage among participants in a randomized, controlled trial of genetic and environmental risk assessment
    Ronald E. Myers, Thomas Jefferson University, Philadelphia, PA

    Is newer better? Use of technology to encourage cancer screening among various populations
    Celette Skinner, UT Southwestern Medical Center, Dallas, TX

    Cost effectiveness of lung cancer screening
    James L. Mulshine, Rush Medical College, Rush University, Chicago, IL

    The effect of the new screening guidelines on uptake of screening tests
    Steve Taplin, National Cancer Institute, Rockville, MD

  • CONCURRENT SESSION 4: NSAIDS AND BEYOND

    Session Chairperson: Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, TX

    Aspirin for cancer prevention: Are we ready?
    Andrew T. Chan, Massachusetts General Hospital, Boston, MA

    A novel approach to biomolecular imaging of COX-2
    Jashim Uddin, Vanderbilt University School of Medicine, Nashville, TN

    Development of NSAID eflornithine combinations for treating cancer risk factors
    Eugene W. Gerner, University of Arizona Cancer Center, Oro Valley, AZ

    Aspirin mediated down-regulation of Warburg Kinase AKT1 in patients with Barrett's Esophagus: Implications in neoplastic transformation *
    Cathrine J. DeMars, Mayo Clinic, Rochester, MN

POSTER SESSION B / LUNCH

12:00 p.m.-2:30 p.m.

  • Behavioral and Social Science
  • Biomarkers and Early Detection Research
  • Cell, Molecular, and Tumor Biology
  • Chemoprevention and Biological Therapies
  • Clinical Prevention Trials (by Organ Site)
  • Epidemiology / Lifestyle Factors
  • Preclinical and Translational Prevention Studies (by Organ Site)

CONCURRENT SESSIONS 5-6

2:30 p.m.-4:15 p.m.

  • CONCURRENT SESSION 5: GLOBAL CHALLENGES: ENVIRONMENTAL CHANGES

    Session Chairperson: Thomas W. Kensler, University of Pittsburgh, Pittsburgh, PA

    Viral and dietary factors in declining liver cancer mortality in Qidong, China
    Thomas W. Kensler

    Arsenic carcinogenesis
    Maria Argos, University of Chicago, Chicago, IL

    Lifestyle, infection, and genetic factors in relation to biliary tract cancer
    Ann W. Hsing, Cancer Prevention Institute of California, Fremont, CA

    Curcumin is an effective chemopreventive substance for betel quid chewer’s oral precancer in Sri Lanka*
    Itsuo Chiba, Health Sciences University of Hokkaido, Sapporo, Japan

  • CONCURRENT SESSION 6: RECENT RESULTS ON MECHANISMS AND PREVENTION OF TOBACCO-INDUCED CANCER

    Session Chairperson: Stephen S. Hecht, University of Minnesota Masonic Cancer Center, Minneapolis, MN

    Induction of oral cavity cancer in rats by (S)-N'-Nitrosonornicotine, a constituent of smokeless tobacco
    Stephen S. Hecht

    Epigenetic deregulation of microRNAs during tobacco carcinogen-induced transformation of bronchial epithelial cells
    Steven A. Belinsky, Lovelace Respiratory Research Institute, Albuquerque NM

    Translating airway gene-expression into biomarkers of smoking and lung cancer
    Avrum E. Spira, Boston University, Boston, MA

    Exposure to tobacco smoke from husband and breast cancer risk in Japanese women *
    Keiko Wada, Gifu University Graduate School of Medicine, Gifu, Japan

PLENARY SESSION 4: GENOMICS AND PREVENTION: WILL GENOMICS LEAD TO OPTIMIZED CANCER PREVENTION?

Session Chairperson: Timothy R. Rebbeck, University of Pennsylvania School of Medicine, Phildelphia, PA
4:15 p.m.-6:15 p.m.

The promise of GWAS studies to assess cancer prevention
Stephen J. Chanock, National Cancer Institute, Bethesda, MD

Insights on cancer risk from normal breast tissue gene expression
Melissa Troester, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

SERM breast cancer prevention pharmacogenomics: Beyond biomarkers
Richard M. Weinshilboum, Mayo Clinic College of Medicine, Rochester, MN

How will genomic information be useful to limit cancer risk behaviors?
Christopher I. Amos, Geisel School of Medicine, Dartmouth College, Lebanon, NH

BEHAVIORAL SCIENCE IN CANCER RESEARCH WORKING GROUP NETWORKING EVENT

6:30 p.m.-8:00 p.m.

MOLECULAR EPIDEMIOLOGY WORKING GROUP TOWN MEETING AND RECEPTION

Chairperson: James R. Cerhan, Mayo Clinic College of Medicine, Rochester, MN
6:30 p.m.-8:00 p.m.

Involvement in consortia and major projects, particularly for junior professionals
Stephen J. Chanock, director, Cancer Genomics Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD

Funding opportunities for new and early-stage investigators
Deborah M. Winn, deputy director, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD

 

FRIDAY, OCTOBER 19 

FORUM 3: HOW TO GAIN ACCESS TO WORLDWIDE COHORTS

Session Chairperson: Mary Beth Terry, Columbia University School of Public Health, New York, NY
7:00 a.m.-8:00 a.m.

Cancer epidemiology consortia and international cohorts: Challenges and opportunities
Daniela Seminara, National Cancer Institute, Bethesda, MD

Worldwide collaborations: The experience of EPIC
Timothy Key, Oxford University, Oxford, United Kingdom

An efficient resource to accelerate research into the cause and prevention of breast cancer: The Love/Avon Army of Women
Leah Wilcox Eshraghi, Dr. Susan Love Research Foundation, Santa Monica, CA

Discussion / Q&A

PLENARY SESSION 5: RISK ASSESSMENT AND EARLY DETECTION

Session Chairperson: Samir M. Hanash, University of Texas MD Anderson Cancer Center, Houston, TX
8:00 a.m.-10:00 a.m.

A mouse to human search for early detection markers
Samir M. Hanash

Translational epidemiology: Towards personalized cancer risk assessment, prevention, and therapy
Michelle A.T. Hildebrand, The University of Texas MD Anderson Cancer Center, Housto, TX

Phenotypic stochasticity and implications for prevention and therapy
Thea Tlsty, UCSF School of Medicine, San Francisco, CA

Pancreatic cancer: The future of risk assessment and early detection
Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN

CONCURRENT SESSIONS 7-8

10:15 a.m.-12:00 p.m.

  • CONCURRENT SESSION 7: TARGETING TUMOR INITIATING CELLS

    Session Chairperson: Robert Benezra, Memorial Sloan-Kettering Cancer Center, New York, NY

    Understanding the role of stem-like tumor cells in proneural glioma
    Robert Benezra

    Targeting tumor-initiating cells in medulloblastoma
    Robert J. Wechsler-Reya, Sanford-Burnham Medical Research Institute, La Jolla, CA

    Chemical-genetic dissection of cancer stem cell biology
    Piyush Gupta, Whitehead Institute for Biomedical Research, Cambridge, MA

    Targeting breast cancer stem cells using cancer preventive rexinoids *
    Powel H. Brown, The University of Texas MD Anderson Cancer Center, Houston, TX

  • CONCURRENT SESSION 8: MOLECULAR TARGETS FOR CANCER PREVENTION

    Session Chairperson: Zigang Dong, University of Minnesota Hormel Institute, Austin, MN

    Computerized approaches to molecularly designed drugs and target identification for cancer prevention
    Zigang Dong

    New strategies for cancer chemoprevention
    Vernon E. Steele, National Cancer Institute, Bethesda, MD

    Targeting molecular pathways in the tumor microenvironment: A holistic approach for cancer chemoprevention
    Rajesh Agarwal, University of Colorado Denver, Aurora, CO

    Novel Gemini vitamin D compounds for prevention of breast cancer by targeting stem cells
    Nanjoo Suh, Rutgers University Laboratory for Cancer Research, Piscataway, NJ

CLOSING REMARKS / DEPARTURE

12:00 p.m.-12:15 p.m.